Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

We are now recruiting volunteers for Oxford Vaccine Group's new Ebola study: Evaluating Optimal Vaccine Schedules against Ebola (EVOLVE)

RECRUITING NOW!

You are invited to take part in a study investigating new vaccines against Ebola virus disease (EVD). The current outbreak of EVD in West Africa is estimated by the World Health Organization to have caused more than 10,000 deaths to date and is still ongoing. There is no specific treatment or cure for Ebola and an effective vaccine would be an important step in controlling the spread of disease. The study is being run by the Oxford Vaccine Group, part of the University of Oxford. 

►       If you are aged 18 to 65 years old and in good health you may be eligible to take part in the study

►       We will provide reimbursement for your time, inconvenience and travel

Interested individuals may attend a screening visit at our site to discuss this further and for their suitability for the study to be assessed.  If you would like to find out more, you can contact us via:

Ebolavaccine.org.uk

01865 857420

info@ovg.ox.ac.uk


This study is being run by the Oxford Vaccine Group, part of the University of Oxford and is funded by Crucell Holland BV.

Similar stories

New clinical trials begin in Burkina Faso

Vaccinations have started at the Institut de Recherche en Sciences de la Santé – Clinical Research Unit of Nanoro (IRSS-URCN), Burkina Faso for two clinical trials to assess the blood-stage malaria vaccine candidates R78C and RH5.1 with Matrix-M (developed by the Draper Lab in the Department of Paediatrics), in combination with the R21/​Matrix-M vaccine, which targets the earlier liver-stage. The trials are sponsored by the University of Oxford (UOXF), UK, with the European Vaccine Initiative (EVI) acting as both a co-funder and collaborator. These exciting studies are expected to provide proof-of-concept for the use of a multi-stage vaccine to extend the protection against malaria and help lead to future efforts to eliminate it by targeting two stages of the parasite’s life-cycle.